RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Phase 2 Not yet recruiting 32 enrolled The First Affiliated Hospital with Nanjing Medical University

NaSingle-groupOpen-labelTreatment

Summary

This study is a prospective, open-label, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery. The study drugs include RC48, Adebrelimab, Apatinib and S-1. The purpose is to evaluate the effectiveness and safety of the combined coordinated treatment of multi-mechanism drugs for perioperative treatment of locally advanced gastric cancer with HER2 overexpression.

Timeline

Start: 2024-05-01
Primary completion: 2027-05-01
Completion: 2028-05-01

Publications

Ding Y, Qian H, Liu H, Zhang J, Zhang X, Wei J, Chen X, Xu H. DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer. J Gastrointest Oncol. 2026 Feb 28;17(1):31. doi: 10.21037/jgo-2025-aw-959. Epub 2026 Feb 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adebrelimab	Monoclonal antibody	1200 mg	Intravenous
Subject	Disitamab Vedotin	Other / unclassified	2.5 mg/kg	Intravenous
Subject	Rivoceranib	Small molecule	250 mg	Oral
Subject	S-1	Small molecule	50 mg	Oral
Subject	S-1	Small molecule	60 mg	Oral

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Summary

Timeline

Publications

Drugs

Indications